Literature DB >> 4660734

Consideration of the subcutaneously implanted B16 melanoma as a screening model for potential anticancer agents.

D P Griswold.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4660734

Source DB:  PubMed          Journal:  Cancer Chemother Rep 2        ISSN： 0069-0120


× No keyword cloud information.
  9 in total

1.  Characterization of the anti-tumour activity against solid tumours of a new nitrosoureido sugar: Cy 233.

Authors:  G Atassi; P Dumont; C Gosse; J P Fournier; A Gouyette; P Roger
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor.

Authors:  R T Dorr; K Dvorakova; K Snead; D S Alberts; S E Salmon; G R Pettit
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  Effects of benzoylphenyl ureas on growth of B16 melanoma cells in vitro and in vivo.

Authors:  H P Hofs; J G McVie
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

4.  [In vitro and in vivo sensitivity of animal and human melanomas to various chemotherapeutical agents].

Authors:  A Wiskemann; M Schussmann; D Rothmann; O Schneider
Journal:  Arch Dermatol Res       Date:  1978-08-28       Impact factor: 3.017

5.  Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.

Authors:  I J Fidler; S Sone; W E Fogler; Z L Barnes
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

Review 6.  Macrophages in cancer metastases and their relevance to metastatic growth.

Authors:  M E Key
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

7.  Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine.

Authors:  I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  Clonogenic assays in the B16 melanoma: response to cyclophosphamide.

Authors:  G G Steel; K Adams; T C Stephens
Journal:  Br J Cancer       Date:  1977-11       Impact factor: 7.640

9.  Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes.

Authors:  Lien Van Hoecke; Sandra Van Lint; Kenny Roose; Alexander Van Parys; Peter Vandenabeele; Johan Grooten; Jan Tavernier; Stefaan De Koker; Xavier Saelens
Journal:  Nat Commun       Date:  2018-08-24       Impact factor: 14.919
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.